Common-Size Income Statement
Quarterly Data
Paying user area
Try for free
Bristol-Myers Squibb Co. pages available for free this week:
- Balance Sheet: Assets
- Analysis of Solvency Ratios
- Analysis of Short-term (Operating) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value (EV)
- Price to FCFE (P/FCFE)
- Return on Equity (ROE) since 2005
- Total Asset Turnover since 2005
- Price to Earnings (P/E) since 2005
- Price to Sales (P/S) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Bristol-Myers Squibb Co. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
Income statement item | Description | The company |
---|---|---|
Operating income (loss) | The net result for the period of deducting operating expenses from operating revenues. | Bristol-Myers Squibb Co. operating income (loss) as a percentage of revenues increased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024. |
Earnings (loss) before income taxes | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. | Bristol-Myers Squibb Co. earnings (loss) before income taxes as a percentage of revenues increased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024. |
Net earnings (loss) attributable to BMS | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. | Bristol-Myers Squibb Co. net earnings (loss) attributable to BMS as a percentage of revenues increased from Q1 2024 to Q2 2024 but then slightly decreased from Q2 2024 to Q3 2024. |